Cover Image

HARDBACK
$52.95



View/Hide Left Panel

including time and monetary costs until a vaccine program is implemented, the annualized present value of the health care costs saved would be $2.9 million.

If a vaccine program for N. meningitidis B were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the program cost would be $720 million. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the program cost would be $450 million.

Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $9 million for a N. meningitidis B vaccine.

If a vaccine program were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is $300,000. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is $400,000.

See Chapters 4 and 5 for details on the methods and assumptions used by the committee for the results reported.

READING LIST

Adams AG, Deaver KA, Cochi SL, et al. Decline of Childhood Haemophilus influenzae Type b (Hib) Disease in the Hib Vaccine Era. JAMA 1993; 269:221–226.

Apicella MA. Neisseria Meningitidis. In: Principles and Practice of Infectious Diseases. GL Mandell, JE Bennett, Dolin R eds. New York, NY: Churchill Livingstone, 1995, pp. 1896–1908.


Bushore M, Marante AA. Emergency Department Stabilization of Pediatric Patients with Bacterial Meningitis—Current Advances. Emergency Medical Clinics of North America; 9:239–250.


Durand ML, Calderwood SB, Weber DJ, et al. Acute Bacterial Meningitis in Adults—A Review of 493 Episodes. The New England Journal of Medicine 1993; 328:21–28.


Frasch CE. Meningococcal Vaccines: Past, Present and Future. In: Meningococcal Disease. K Cartwright ed. New York, NY: John Wiley & Sons Ltd., 1995, pp. 245–283.


Glode MP, Smith AL. Meningococcal Disease. In: Textbook of Pediatric Infectious Diseases. RD Feigin and JD Cherry eds. Philadelphia, PA: WB Saunder Company, 1992, pp. 1185–1197.


Jackson LA, Wenger JD. Laboratory-Based Surveillance for Meningococcal Disease in Selected Areas, United States, 1989–1991. Morbidity and Mortality Weekly Report 1993; 42:21–30.


Milagres LG, Ramos SR, Sacchi CT, et al. Immune Response of Brazilian Children to a Neisseria meningitidis Serogroup B Outer Membrane Protein Vaccine: Comparison with Efficacy. Infection and Immunity 1994; 62:4419–4424.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement